SCHEMBL20165945

SCHEMBL20165945

CC(C)(C)OC(=O)N1CC(Oc2c(F)cc(F)cc2F)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.43
GPR119 Q8TDV5 2/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.41
NR1H2 P55055 1/20 0.40
DPP4 P27487 1/20 0.40
RORC P51449 1/20 0.39
CACNB4 O00305 1/20 0.39
CACNA1A O00555 1/20 0.39
CACNA1G O43497 1/20 0.39
CACNG3 O60359 1/20 0.39
CACNA1F O60840 1/20 0.39
CACNA1H O95180 1/20 0.39
CACNB3 P54284 1/20 0.39
CACNA2D1 P54289 1/20 0.39
CACNG7 P62955 1/20 0.39
CACNA1B Q00975 1/20 0.39
CACNA1D Q01668 1/20 0.39
CACNB1 Q02641 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20439309 0.89 USP30 (0.52) USP30GPR119HDAC1HDAC2NR1H2
SCHEMBL22817815 0.86 USP30 (0.43) USP30GPR119HDAC1HDAC2NR1H2
SCHEMBL22817830 0.85 GPR119 (0.43) USP30GPR119HDAC1HDAC2SMN1; SMN2
SCHEMBL22265869 0.84 USP30 (0.46) USP30GPR119HDAC1HDAC2NR1H2
SCHEMBL22817807 0.82 NR1H2 (0.44) USP30GPR119HDAC1HDAC2SMN1; SMN2
SCHEMBL20166094 0.82 USP30 (0.42) USP30GPR119NR1H2DPP4RORC
SCHEMBL22817811 0.81 GPR119 (0.48) USP30GPR119NR1H2DPP4CACNB4
SCHEMBL20165784 0.81 GPR119 (0.49) USP30GPR119HDAC1HDAC2NR1H2
SCHEMBL19729447 0.80 SMN1; SMN2 (0.40) USP30GPR119HDAC1HDAC2SMN1; SMN2
SCHEMBL20165884 0.79 RIPK1 (0.38)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3541784-B1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) 2023-09-13 EP disclosed
CN-109963834-B Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission 综合研究实验室瑞典股份公司 2023-04-14 CN disclosed
US-10875829-B1 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2020-12-29 US disclosed
EP-3541784-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION Integrative Research Laboratories Sweden AB (SE) 2019-09-25 EP disclosed
WO-2018091687-A1 NOVEL AZETIDINE DERIVATIVES USEFUL AS MODULATORS OF CORTICAL CATECHOLAMINERGIC NEUROTRANSMISSION INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) 2018-05-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10875829-B1 Azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission SLC18A1, CHRM1, CHRM2 USP30 1863/4885GPR119 55/4885HDAC1 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.